The study, published by New York University, was not reviewed or published in a scientific journal, but was based on a series of laboratory experiments with blood samples, which means it does not reflect the effective use of the vaccine in humans.
However, the study authors suggest that people who receive a single dose of this vaccine, made in Janssen laboratories of the multinational Johnson & Johnson, should receive a booster vaccination, preferably with the Pfizer or Moderna vaccine.
These findings contradict recent studies published by Johnson & Johnson, which indicated that the covid-19 vaccine and the Delta variant were highly effective within eight months of vaccination.
“We want to get the message across to us that people are not stopping the Johnson & Johnson vaccine, but we hope there will be a revaccination in the future with a different dose of the same vaccine from Pfizer or Moderna,” he said. virologist Nathaniel Landau, who led the study, is cited by The New York Times.
At a Senate hearing on Tuesday, the director of the US Centers for Disease Control and Prevention, Rochelle Walensky, said the delta variant of covid-19, which is more contagious, currently accounts for 83% of infections in the United States.
According to the latest report from Agence France-Presse, the covid-19 pandemic has caused at least 4,119,920 deaths worldwide out of more than 191.3 million cases of the novel coronavirus.
The respiratory illness is caused by the SARS-CoV-2 coronavirus, discovered at the end of 2019 in Wuhan, a city in central China, and currently variants identified in countries such as the UK, India, South Africa, Brazil and Peru.
